Dalane Kitzman to Glucagon-Like Peptide 1
This is a "connection" page, showing publications Dalane Kitzman has written about Glucagon-Like Peptide 1.
Connection Strength
0.405
-
Pandey A, Kitzman DW, Chinnakondepalli KM, Patel S, Borlaug BA, Butler J, Davies MJ, Shah SJ, Verma S, Rönnbäck C, Domdey A, Liisberg K, Schou M, Perna E, Ahmed FZ, Fu M, Petrie MC, Kosiborod MN. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC Heart Fail. 2025 Oct; 13(10):102610.
Score: 0.233
-
Pandey A, Moroney M, Verma S, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Petrie MC, Rönnbäck C, Domdey A, Rasmussen S, Chinnakondepalli KM, Patel S, Kosiborod MN. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. Eur J Heart Fail. 2025 Nov; 27(11):2537-2543.
Score: 0.059
-
Borlaug BA, Kitzman DW, Patel S, Chinnakondepalli KM, Butler J, Davies MJ, Petrie MC, Shah SJ, Verma S, Núñez J, Einfeldt MN, Liisberg K, Salsali A, Kosiborod MN. Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. JACC Heart Fail. 2025 Nov; 13(11):102660.
Score: 0.058
-
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):196-209.
Score: 0.056